Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) - Net Assets
Latest net assets as of September 2025: CN¥3.13 Billion CNY
Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has net assets worth CN¥3.13 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.69 Billion) and total liabilities (CN¥3.56 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.13 Billion |
| % of Total Assets | 46.85% |
| Annual Growth Rate | 82.04% |
| 5-Year Change | 177.67% |
| 10-Year Change | 3558.48% |
| Growth Volatility | 339.77 |
Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Net Assets Trend (2013–2024)
This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2024)
The table below shows the annual net assets of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.68 Billion | +22.52% |
| 2023-12-31 | CN¥2.19 Billion | +13.74% |
| 2022-12-31 | CN¥1.92 Billion | +6.42% |
| 2021-12-31 | CN¥1.81 Billion | +87.24% |
| 2020-12-31 | CN¥966.02 Million | +15.14% |
| 2019-12-31 | CN¥838.98 Million | +6.82% |
| 2018-12-31 | CN¥785.38 Million | +144.52% |
| 2017-12-31 | CN¥321.20 Million | +818.95% |
| 2016-12-31 | CN¥34.95 Million | -52.33% |
| 2015-12-31 | CN¥73.32 Million | +441.46% |
| 2014-12-31 | CN¥-21.47 Million | -682.62% |
| 2013-12-31 | CN¥3.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 76872296758.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥722.41 Million | 27.15% |
| Common Stock | CN¥219.78 Million | 8.26% |
| Other Comprehensive Income | CN¥161.20 Million | 6.06% |
| Other Components | CN¥1.56 Billion | 58.52% |
| Total Equity | CN¥2.66 Billion | 100.00% |
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tansun Technology Co Ltd
SHE:300872
|
$802.51 Million |
|
Banca IFIS S.p.A.
LSE:0NBX
|
$802.81 Million |
|
Jiangsu Shentong Valve Co Ltd
SHE:002438
|
$802.89 Million |
|
Zhengzhou GL Tech Co Ltd
SHE:300480
|
$803.21 Million |
|
KRUNGTHAI CARD FGN BA 1
F:KRTA
|
$801.94 Million |
|
Global Power Synergy Public Company Limited
BK:GPSC-R
|
$801.90 Million |
|
Yantai China Pet Foods Co Ltd
SHE:002891
|
$801.80 Million |
|
KPC Pharmaceuticals Inc
SHG:600422
|
$801.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinopep-Allsino Biopharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,170,268,338 to 2,660,367,000, a change of 490,098,662 (22.6%).
- Net income of 404,389,996 contributed positively to equity growth.
- Dividend payments of 118,751,746 reduced retained earnings.
- Other comprehensive income increased equity by 161,204,908.
- Other factors increased equity by 43,255,504.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥404.39 Million | +15.2% |
| Dividends Paid | CN¥118.75 Million | -4.46% |
| Other Comprehensive Income | CN¥161.20 Million | +6.06% |
| Other Changes | CN¥43.26 Million | +1.63% |
| Total Change | CN¥- | 22.58% |
Book Value vs Market Value Analysis
This analysis compares Sinopep-Allsino Biopharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 439.61x to 2.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.07 | CN¥32.08 | x |
| 2014-12-31 | CN¥-0.43 | CN¥32.08 | x |
| 2015-12-31 | CN¥1.46 | CN¥32.08 | x |
| 2016-12-31 | CN¥0.58 | CN¥32.08 | x |
| 2017-12-31 | CN¥2.83 | CN¥32.08 | x |
| 2018-12-31 | CN¥5.67 | CN¥32.08 | x |
| 2019-12-31 | CN¥3.91 | CN¥32.08 | x |
| 2020-12-31 | CN¥6.07 | CN¥32.08 | x |
| 2021-12-31 | CN¥8.50 | CN¥32.08 | x |
| 2022-12-31 | CN¥8.96 | CN¥32.08 | x |
| 2023-12-31 | CN¥10.12 | CN¥32.08 | x |
| 2024-12-31 | CN¥12.10 | CN¥32.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinopep-Allsino Biopharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.20%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.89%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.91x
- Recent ROE (15.20%) is above the historical average (-46.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -370.00% | 0.00% | 0.00x | 45.26x | CN¥-14.00 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | CN¥-23.01 Million |
| 2015 | -41.13% | -343.55% | 0.04x | 2.68x | CN¥-37.49 Million |
| 2016 | -213.99% | -879.02% | 0.05x | 4.58x | CN¥-78.29 Million |
| 2017 | 13.05% | 18.32% | 0.37x | 1.90x | CN¥9.81 Million |
| 2018 | 5.64% | 17.18% | 0.24x | 1.35x | CN¥-33.93 Million |
| 2019 | 5.83% | 13.08% | 0.30x | 1.49x | CN¥-34.82 Million |
| 2020 | 12.81% | 21.78% | 0.41x | 1.45x | CN¥27.11 Million |
| 2021 | 6.37% | 17.92% | 0.30x | 1.17x | CN¥-65.75 Million |
| 2022 | 6.76% | 19.82% | 0.26x | 1.32x | CN¥-61.92 Million |
| 2023 | 7.51% | 15.76% | 0.29x | 1.63x | CN¥-54.09 Million |
| 2024 | 15.20% | 24.89% | 0.32x | 1.91x | CN¥138.35 Million |
Industry Comparison
This section compares Sinopep-Allsino Biopharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) | CN¥3.13 Billion | -370.00% | 1.13x | $802.48 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |